Summary:
This study is designed to prospectively confirm the efficacy of a fixed-dose regimen of cariprazine 1.5 mg/day or 3 mg/day compared to placebo for treatment of the depressive episode in patients with bipolar I disorder. The safety and tolerability of the fixed-dose regimens will be evaluated.
Qualified Participants Must:
• Be between 18 and 65 years of age (Adult)
•
Be currently treated as an outpatient at the time of enrollment
•
Have a verified previous manic or mixed episode.
Qualified Participants May Receive:
Study-related medical care and investigational drug at no cost and may be compensated for time and travel.